1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Benign Neoplasms, Brain in 7 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 7.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 3.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| "Malignant gliomas are characterized by high invasive potential and strong angiogenic ability." | 1.37 | HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. ( Nakabayashi, H; Shimizu, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Liu, X | 1 |
| Zhou, W | 1 |
| Yang, M | 1 |
| Ding, Y | 1 |
| Wang, Q | 1 |
| Hu, R | 1 |
| He, M | 1 |
| Luo, M | 1 |
| Liu, Q | 1 |
| Chen, J | 1 |
| Li, K | 1 |
| Zheng, M | 1 |
| Weng, Y | 1 |
| Ouyang, L | 1 |
| Liu, A | 1 |
| Shenkar, R | 1 |
| Shi, C | 1 |
| Austin, C | 1 |
| Moore, T | 1 |
| Lightle, R | 1 |
| Cao, Y | 1 |
| Zhang, L | 1 |
| Wu, M | 1 |
| Zeineddine, HA | 1 |
| Girard, R | 1 |
| McDonald, DA | 1 |
| Rorrer, A | 1 |
| Gallione, C | 1 |
| Pytel, P | 1 |
| Liao, JK | 1 |
| Marchuk, DA | 1 |
| Awad, IA | 1 |
| Nakabayashi, H | 1 |
| Shimizu, K | 1 |
| Kugaya, A | 1 |
| Kagaya, A | 1 |
| Uchitomi, Y | 1 |
| Motohashi, N | 1 |
| Yamawaki, S | 1 |
| Van Wagoner, NJ | 1 |
| O'Keefe, GM | 1 |
| Benveniste, EN | 1 |
| Miñana, MD | 1 |
| Felipo, V | 1 |
| Cortés, F | 1 |
| Grisolía, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Combination treatment with fasudil and clioquinol produces synergistic anti-tumor effects in U87 glioblastoma cells by activating apoptosis and autophagy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Autophagy; Blotting, Western; Bra | 2016 |
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Neoplasms; Disease Models, Animal; Fem | 2017 |
HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Blotting, Western; Brain Neopl | 2011 |
Inhibition of serotonin-induced Ca2+ mobilization by interleukin-1 beta in rat C6BU-1 glioma cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Neoplasms; Calcium; Cell Division; Enz | 1995 |
Kinase inhibitors abrogate IFN-gamma-induced class II transactivator and class II MHC gene expression in astroglioma cell lines.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Astrocytoma; Brain Neoplasms; Enzyme Inhibitors; Gene | 1998 |
Inhibition of protein kinase C arrests proliferation of human tumors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Ce | 1991 |